Scotiabank Maintains ARS Pharmaceuticals(SPRY.US) With Buy Rating, Maintains Target Price $30
ARS Pharmaceuticals (SPRY) Gets a Buy From Scotiabank
William Blair Maintains ARS Pharmaceuticals(SPRY.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: ARS Pharmaceuticals (SPRY) and Stryker (SYK)
William Blair Reaffirms Their Buy Rating on ARS Pharmaceuticals (SPRY)
Raymond James Maintains ARS Pharmaceuticals(SPRY.US) With Buy Rating, Maintains Target Price $32
ARS Pharmaceuticals: Strategic Growth and Market Penetration Justify Buy Rating
Raymond James Maintains ARS Pharmaceuticals(SPRY.US) With Buy Rating, Raises Target Price to $32
Scotiabank Maintains ARS Pharmaceuticals(SPRY.US) With Buy Rating, Maintains Target Price $30
William Blair Maintains ARS Pharmaceuticals(SPRY.US) With Buy Rating
ARS Pharmaceuticals: Strong Market Performance and Strategic Advancements Drive Buy Rating
Scotiabank Initiates Coverage On ARS Pharmaceuticals With Sector Outperform Rating, Announces Price Target of $30
ARS Pharmaceuticals Analyst Ratings
Leerink Partners Maintains ARS Pharmaceuticals(SPRY.US) With Buy Rating, Maintains Target Price $27
ARS Pharmaceuticals: Strategic Developments and Market Opportunities Drive Buy Rating for Neffy
William Blair Maintains ARS Pharmaceuticals(SPRY.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: ARS Pharmaceuticals (SPRY) and Corbus Pharmaceuticals (CRBP)
William Blair Maintains ARS Pharmaceuticals(SPRY.US) With Buy Rating
William Blair Initiates ARS Pharmaceuticals(SPRY.US) With Buy Rating
Oppenheimer Maintains ARS Pharmaceuticals(SPRY.US) With Buy Rating, Raises Target Price to $40